Novo Nordisk A/S

• Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial   - The drugmaker is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill. 
• Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site - The announcement comes weeks after President Donald Trump inked deals with Eli Lilly and Novo Nordisk to make their GLP-1 drugs easier for Americans to access.